Bristol Myers reports Q3 adjusted EPS $1.63, consensus $1.52

Reports Q3 revenue $12.22B, consensus $11.8B. “We delivered strong results this quarter as a result of continued execution across the business and ongoing Growth Portfolio momentum,” said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers (BMY) Squibb. “We’re focused on building for the future by accelerating innovation, advancing our pipeline, staying agile and delivering more transformational medicines to more patients.”